ArticleJBMR plus2026
Early bone-formation response to sclerostin antibody is altered by prior antiresorptive treatment in ovariectomized rats.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore how preceding treatment with a bisphosphonate (BP) and/or OPG-Fc, a RANKL inhibitor, affects early bone formation (BF) response to sclerostin antibody (Scl-Ab) in vertebral cancellous and cortical bone, we treated ovariectomized rats with various sequences of vehicle (Veh), OPG-Fc, and alendronate (Aln) or zoledronic acid (ZOL) in cycle 1 (0-12 wk) or cycle 2 (12-18 wk) before administering Scl-Ab in cycle 3 (18-24 wk). Treatment sequences included Veh/Veh/Scl-Ab (treatment naïve), OPG-Fc/OPG-Fc/Scl-Ab, OPG-Fc/ZOL/Scl-Ab, Aln/OPG-Fc/Scl-Ab, and OPG-Fc/OPG-Fc_Veh/Scl-Ab (4-wk treatment-free period preceding Scl-Ab). DXA scans and serum bone turnover markers were assessed. Cancellous and endocortical histomorphometric endpoints were quantified at weeks 18, 20, and 24. With Veh/Veh/Scl-Ab, anticipated bone responses to Scl-Ab were observed. From week 18 to week 24, Scl-Ab-mediated bone mass accrual was blunted with preceding antiresorptive sequences. In groups where OPG-Fc immediately preceded Scl-Ab, BF suppression was marked at week 20 with limited modeling-based bone formation (MBBF). In contrast, when ZOL was interposed between OPG-Fc and Scl-Ab, MBBF was modestly reduced at week 20. By week 24, BF surfaces were generally similar in all groups; the contribution of MBBF and remodeling-based bone formation (RBBF) differed. In contrast to other antiresorptive sequences, in OPG-Fc/OPG-Fc_Veh/Scl-Ab, RBBF was also a significant contributor to bone forming surfaces, reflecting a rebound in resorption and remodeling. With the other antiresorptive sequences, MBBF was the major contributor to BF, consistent with prolonged suppression of remodeling at week 24. All prior antiresorptive sequences blunted Scl-Ab effects on early BF. BP exposure (before or after OPG-Fc) improved cumulative effects across all cycles on bone mass compared with OPG-Fc alone. Interposing ZOL between OPG-Fc and Scl-Ab improved the early BF response to Scl-Ab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.